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Deciding which needle to use when performing transjugular 
iver biopsy (TJLB) is still debated, as no clear-cut indication has 
et been provided. There are several reasons why it is difficult to 
rovide adequate guidelines on this topic, including the lack of a 
eference standard to define an adequate liver sample, very het- 
rogenous populations with different patient and liver characteris- 
ics, and a lack of randomized controlled trials (RCTs) comparing 
ifferent needles. 
Liver biopsy specimens represent approximately 1/50,0 0 0 of the 
iver. In chronic liver disease, both a minimum length of liver spec- 
men and a minimum number of portal tracts has been estab- 
ished to obtain an optimal histological evaluation. From a diagnos- 
ic point of view, a specimen of > 15 mm length with more than 6
ortal tracts is considered sufficient [1] , while a specimen of 20–
5 mm length or > 11 complete portal tracts is deemed necessary 
o reliably assess grading and staging [2] . It is clear that a long and
ot fragmented specimen is best, in order to obtain a correct diag- 
osis. Unfortunately, this goal is rarely obtained by TJLB, especially 
n fibrotic liver, in which fragmentation of the specimen is quite 
ommon and the number of portal tracts is low due to architec- 
ural distortion of the liver. The increased number of passages can 
artially remedy this pitfall, but it is still hard to define which is 
he best needle to use in order to minimize these biases. The aspi- 
ation needle and the Tru-cut needle are the most commonly used 
eedle types in TJLB. 
The largest metanalysis of all papers on TJLB was published 
ore than 10 years ago and it included 7649 procedures (3). It re- 
orted a success rate in providing adequate liver samples in 96.1% 
f the patients, with a mean number of passes per procedure 2.7, 
 fragmentation rate of sample 34.3%, a median specimen length 
2 mm (range 3.3–28), and a median number of portal tracts 6.5 
range 2.7–11). The specimens obtained with the Tru-Cut needle 
ere more adequate for histological diagnosis than those obtained 
ith a Menghini needle ( p < 0.001) using a similar number of 
asses. In cirrhotic patients, the Menghini needle specimens were 
ignificantly more fragmented than the Tru-cut (35.2% vs. 11.4%) 
nes and significantly longer specimens were achieved using 
he Tru-Cut needle median (14.5 mm vs 9.5 mm, p = 0.008). This 
esult is in line with a previous study comparing Menghini and 
ru-Cut needles, which reported the superiority of the Tru-Cut in 
irrhotic patients undergoing percutaneous liver biopsy [4] and 
s also in line with the results of a small RCT, comparing two 
emi-automated needles for TJLB [5] . More recent devices have 
ade the procedure easier and quicker, but have not substantially ttps://doi.org/10.1016/j.dld.2020.10.013 
590-8658/© 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All mpacted the quality of the liver specimen obtained with TJLB. 
verall, despite many attempts to compare the needles used to 
erform TJLB, it is difficult to determine the best needle to be 
sed when performing TJLB, due to the lack of RCTs. The paper by 
tift et al., published in this issue [6] , introduces a relevant new 
ariable, linking the choice of the needle to the grade of fibrosis 
xpected, depending on portal hypertension and liver stiffness 
LS). This policy is in line with previous observations which have 
eported less fragmented specimens using the Tru-cut needle in 
irrhotic patients and longer specimens using the aspiration nee- 
le in patients without severe fibrosis [3] . The recent possibility to 
easure the stiffness of the liver with non-invasive techniques is 
 valuable tool which makes this strategy achievable. 
In the study by Stift et al. [6] , the authors suggest stratifying pa-
ients undergoing TJLB according to hepatic venous pressure gradi- 
nt (HVPG), in order to choose the best tool (aspiration vs. Tru-cut 
eedle) for obtaining adequate and less fragmented liver speci- 
ens. HVPG is the measure of portal hypertension and one of the 
trongest predictors of clinical decompensation in patients with 
ompensated cirrhosis [7] . Stift et al. [6] show that in patients with 
linically significant portal hypertension (CSPH), defined as HVPG 
f at least 10 mmHg, in whom fibrous septa are mostly thick [8 , 9] ,
he Tru-cut needle performs better, in terms of a lower proportion 
f fragmented liver samples (more than 6 out of 10 not fragmented 
ith Tru-cut needle vs. 2 out of 10 not fragmented specimens 
ith aspiration needle; p = 0.01). By contrast, in patients with 
ild or absent portal hypertension (HVPG < 10 mmHg), in whom 
brous septa are more frequently thin [8 , 9] , the aspiration needle 
erforms better, in terms of greater sample length and proportion 
f liver specimen equal or longer than 2 cm (more than 5 out of 10
iver samples ≥2 cm obtained with aspiration needle vs. 1 out of 
0 obtained with tru-cut needle; p = 0.02). Furthermore, LS mea- 
ured by vibration-controlled transient elastography (VCTE) is an 
merging tool that could guide the decision on which needle type 
s best for TJLB: aspiration needles perform better for TJLB when 
he liver tissue is softer (LS < 20 kPa) and Tru-cut needles are su- 
erior in terms of diagnostic quality in the presence of stiffer livers 
LS > 40 kPa). This finding is not unexpected since LS is a predictor 
f hepatic fibrosis and an accurate non-invasive surrogate measure 
f portal hypertension. The diagnosis of CSPH is made possible 
y VCTE, with an accuracy greater than 80%, when using a binary 
ut-off approach [10] . LS > 20 kPa is the cut-off useful to rule-in 
SPH, defining the group of patients at risk of having endoscopic 
igns of portal hypertension. The vast data available regarding the rights reserved. 
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elationship between LS and CSPH led the Baveno VI consensus 
onference on portal hypertension to suggest a simple combi- 
ation of LS measured by VCTE ( < 20 kPa) and platelet count 
 > 150,0 0 0/mcl) in order to identify patients with viral-related 
dvanced chronic liver disease at low risk of varices needing treat- 
ent and in whom endoscopic screening could be safely avoided 
11] . However, every clinical algorithm including a LS cut-off as a 
atershed can be safely applied only if clinicians take into account 
ny possible influencer or confounder of LS on an individual basis 
nd on the etiology of the liver disease at hand. For instance, 
hen using LS as a tool for stratifying patients, caution should 
e paid in patients with acute flares of transaminases, since 
ecroinflammatory activity is an influencer of LS [12 , 13] , and it is
ikely due to tissue oedema accompanying liver cell necrosis and 
welling of liver cells occurring in the course of the inflammatory 
rocess. Thus, keeping this in mind when planning a TJLB is useful 
ince knowing at an earlier stage whether the liver is stiff or soft 
ight be of help in choosing the best needle to use to obtain 
etter specimen quality: aspiration needles for softer livers, and 
ru-cut needles for stiffer livers. However, at this point, large 
rospective RCTs comparing TJLB techniques are needed before 
ny recommendation can be made. 
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